Riboflavin 5-Phosphate Ophthalmic Solution shortage
Riboflavin 5-Phosphate Ophthalmic Solution is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 23, 2026.
Glaukos Corporation is stopping production of Riboflavin 5-Phosphate eye drops, and this change may be permanent. No other manufacturers of this medicine are currently listed, so it may not be available from other sources.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Riboflavin 5-Phosphate Ophthalmic Solution. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jan 20, 2026Currently in shortage1 of 1 product affected.
-
Jan 20, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Glaukos Corporation 📞 949-367-9600 1 NDC click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03) | — | — | Discontinuing manufacture of the product as of July 2026. | — |
These rows are manufacturer reports to the FDA for Riboflavin 5-Phosphate Ophthalmic Solution — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Riboflavin 5-Phosphate Ophthalmic Solution? options further down this page.
Why is Riboflavin 5-Phosphate Ophthalmic Solution in shortage?
Glaukos Corporation has let the FDA know that they are permanently stopping the manufacturing of their Photrexa Cross-linking Kit (the ophthalmic solution kit, NDC 25357-025-03) as of July 2026. That's the specific product that is on the shortage list — it won't be made after that date.
The manufacturer did not share a specific public reason for why they made this decision — just that the discontinuation is planned for July 2026. It's worth knowing that this report reflects only what Glaukos filed with the FDA, so it speaks only to their product and timeline.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Riboflavin 5-Phosphate Ophthalmic Solution, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Riboflavin 5-Phosphate Ophthalmic Solution?
Riboflavin 5-Phosphate ophthalmic solution is currently on the FDA shortage list, and the reason listed is important to understand.
According to the manufacturer report, Glaukos Corporation plans to discontinue making this product (the Photrexa Cross-linking Kit) as of July 2026. Because this is a planned discontinuation rather than a temporary manufacturing delay, this supply problem may become permanent. Only one manufacturer is on this record, and no other same-medicine sources appear in our records at this time.
Even so, please know that a discontinuation date in the future does not mean the product is gone today. Supply may still be available now, and your care team can help you plan ahead.
Here is what I suggest:
- Do not stop, skip, or change how you use this medicine on your own.
- Ask your pharmacy to check whether stock is still available through wholesalers or the manufacturer.
- Because this product is set to be discontinued, talk with your prescriber or eye specialist about the right next step for your treatment plan.
- The manufacturer's phone number is listed on this page for reference; pharmacies usually handle these calls.
This is general information from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths / sizes, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Photrexa Cross-linking Kit | Glaukos | 2 pouches | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Riboflavin 5-Phosphate Ophthalmic Solution — that fall in the same broad treatment class (agents for corneal collagen cross-linking) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other ophthalmology shortages
Riboflavin 5-Phosphate Ophthalmic Solution shortage FAQs
Is Riboflavin 5-Phosphate Ophthalmic Solution in shortage?
Which products are affected?
When will Riboflavin 5-Phosphate Ophthalmic Solution be available again?
What should I do if I take Riboflavin 5-Phosphate Ophthalmic Solution?
Still have a question about the Riboflavin 5-Phosphate Ophthalmic Solution shortage?
Ask a pharmacist about this shortage →View Riboflavin 5-Phosphate Ophthalmic Solut... on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.